This study evaluates the effect that fasting has on nausea before, during and after chemotherapy.
Participants must have chemotherapy infused all in one day.
Exclusions include, but are not limited to: Weight loss of more than 5% over the past 6 months, diabetes, hypoglycemia, syncope history, active ulcer disease, elevated uric acid, chronic steroid usage and medications that are unsafe to take without food.
Clinical Trial #V212-011:
The use of a vaccine versus placebo to help prevent shingles in patients who are receiving chemotherapy.
Participants must be over 18 years of age and receiving chemotherapy OR 50 years of age and older with cancers of the blood not receiving Rituxan. All participants must have a history of chicken pox or antibodies.
Exclusions include, but are not limited to: Allergy to neomycin, history of shingles in the past year, prior shingles vaccine, Rituxan within the past 3 months or any live vaccine within the past 4 weeks.
Clinical Trial # 031-00:
Nausea and vomiting prevention using intravenous Emend or placebo with Ondansetron or Dexamethasone for patients with confirmed malignant disease who will be receiving their first moderate to high dose of emetogenic chemotherapy.
Exclusions include, but are not limited to: Usage of Coumadin, active infections or central nervous system malignancy that is already causing nausea or vomiting.